Uncategorized

Inhibitec has received funding ((€3,533.45) through the Planes de Promoción Comercial program (NM25-PC-109), supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN). This grant allowed us to cover 50% of the funding for three international activities, which are part of its strategy to increase international visibility, open new markets, and expand its network of […]

Inhibitec Antibodies has been selected for the ‘Programa Personal Técnico I+D’, supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN), enabling us to expand our scientific team with the addition of a new R&D technician (RH25-XX-011). We sincerely appreciate SODERCAN’s continued support for Inhibitec since the early stages of our project.

Inhibitec Antibodies has been one of the startups selected in the ‘Programa Personal Tecnico I+D’ supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN) to expand its scientific team with the addition of an R&D technician (RH23-XX-025). We greatly appreciate the support of SODERCAN for Inhibitec since the beginning of our project. https://boc.cantabria.es/boces/verAnuncioAction.do?idAnuBlob=386579

Towards a new therapy in psoriasis and psoriatic arthritis Inhibitec Anticuerpos S.L. has been selected as a recipient of the grant CPP2022-009666, supporting the development of the public–private collaborative project “Towards a new therapy in psoriasis and psoriatic arthritis”, within the framework of the Plan Estatal de Investigación Científica, Técnica y de Innovación (PEICTI) 2021–2023.

Inhibitec is selected as finalist in the BIO-Europe Spring Startup Spotlight competition. This exciting competition offers entrepreneurs an affordable opportunity to engage with top-tier investors and other important players in the biotech industry to take their business to the next level. Link to the article

World Lupus Day was celebrated on 10th May. At Inhibitec we were very proud to share our progress on the effects of BAMBI deficiency in the development of Lupus during the Annual IMMUNOLOGY 2023 conference held in Washington DC.

Inhibitec’ s team had the privilege to participate in BIOSPAIN 2023, one of the main international biotechnology events in southern Europe, held in Barcelona. This was a dynamic conference marked by numerous meetings we had which offered the great opportunity to share our innovative therapy for Psoriatic Arthritis with potential investors and collaborators. This platform

Inhibitec has been officially recognized by ENISA (Empresa Nacional de Innovacion, S.A) as an outstanding emerging company, being the first to obtain this certificate in Cantabria. This recognition confirms Inhibitec’s commitment and potential in the field of innovation and technology, solidifying its position as a reference point in the region. For more details about this

Towards a novel disruptive therapy in autoimmune disease We are thrilled to announce that Inhibitec has been selected as a recipient of the NEOTEC 2021 grant provided by CDTI (Center for Industrial Technological Development) with the support of the Ministerio de Ciencia e Innovación. This prestigious grant is designed to impulse new entrepreneurial projects that

Inhibitec Antibodies, S.L. Cantabrian biotechnology company, spin-off of the CSIC and University of Cantabria, has developed a monoclonal antibody for a new therapeutic target. Last week,  it was in Cambridge, within the Idea Spark Program designed by MIT and SODERCAN.  A significant number of psoriatic patients with severe disease do not respond to existing therapies.